Vaxcyte Strikes up to $1B Fill-Finish Manufacturing Deal with Thermo Fisher at North Carolina Facility

Vaxcyte announced an agreement with Thermo Fisher Scientific valued at up to $1 billion for fill-finish commercial manufacturing and related services at Thermo Fisher's Greenville, North Carolina facility24.

This deal is a cornerstone of Vaxcyte’s long-term U.S. commercial supply strategy, expanding domestic manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates246.

The agreement aims to strengthen Vaxcyte's U.S. supply chain, enhance commercial readiness, and increase investment in American innovation, infrastructure, and biomanufacturing jobs246.

Key products in development for Vaxcyte include VAX-31 and VAX-24, both broad-spectrum pneumococcal conjugate vaccines aiming to protect against serious bacterial diseases6.

The initiative aligns with growing U.S. government and industry emphasis on domestic vaccine production resilience and end-to-end supply chain management24.

Thermo Fisher's facility will provide custom commercial fill-finish capacity for Vaxcyte's vaccines, supporting future commercial launches in the U.S.24.

The financial commitment involved, up to $1 billion, further underscores the expected scale and long-term scope of the collaboration245.

Sources:

2. https://www.marketscreener.com/news/vaxcyte-to-establish-fill-finish-manufacturing-in-north-carolina-as-key-element-of-long-term-united-ce7d5bd8da88f522

4. https://www.globenewswire.com/news-release/2025/09/30/3158591/0/en/Vaxcyte-to-Establish-Fill-Finish-Manufacturing-in-North-Carolina-as-Key-Element-of-Long-Term-United-States-Commercial-Supply-Strategy-Representing-Up-to-1-Billion-in-Manufacturing-.html

5. https://stockstory.org/us/stocks/nyse/tmo/news/why-up-down/why-thermo-fisher-tmo-stock-is-trading-up-today-2

6. https://www.quiverquant.com/news/Vaxcyte+and+Thermo+Fisher+Scientific+Sign+Agreement+to+Enhance+U.S.+Manufacturing+for+Pneumococcal+Vaccine+Candidates